Is BPC 157 Banned? Oral vs. Injectable Forms Explained FDA to weigh easing limits on unproven peptides Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide The Human Lab Rats Injecting Themselves with Peptides Office for Science and Society McGill University